SSRIs: bad to the bone?
Level 5 - mechanism / opinion, no new human data
Narrative literature review without systematic methodology
What was done
The authors performed a narrative review of 19 studies, one review, and one meta-analysis to evaluate the association between selective serotonin reuptake inhibitor (SSRI) use, bone mineral density, and fracture risk, along with mechanistic evidence on bone cell lines.
What was found
The abstract reports no numerical values, effect estimates, or confidence intervals. It qualitatively reports that all reviewed studies indicated negative effects of SSRIs on bone mineral density and fracture risk, with potential enhancement by longer exposure or more serotonergic agents. Serotonin receptors were also noted on osteoclasts, osteoblasts, and osteocytes.
Why it matters
This paper aggregates evidence on a clinically significant potential adverse effect of SSRIs, suggesting caution when prescribing these agents to patients with preexisting osteoporosis or prior osteoporotic fractures.
Limits
The abstract provides no quantitative data. As a narrative review, it lacks systematic search criteria or formal risk-of-bias assessment, and the authors explicitly note that substantial confounding in the primary studies obscures the true effect magnitude.
Cited by
- context A standard dose of Prozac (fluoxetine) causes as much damage to bone integrity as extended use of prednisone.